Research
Hormonal
Tirzepatide (up to 15 mg weekly) achieves the highest mean weight loss (up to 20.9%) among current pharmacotherapies but lacks FDA approval for cardiovascular risk reduction.
Tirzepatide (up to 15 mg weekly) offers the highest weight loss potential (up to 20.9%) among current drugs. However, it is not yet FDA-approved for cardiovascular risk reduction. Titrate the dose slowly to manage gastrointestinal side effects.
StrongSupportsVERY_HIGH confidence
Tirzepatide leads at 20.9%, though it lacks FDA approval for CV risk reduction or adolescent use [56]. In SURMOUNT-1... tirzepatide led to 15.0-20.9% weight loss vs. 3.1% with placebo over 72 weeks...
Why this rating
Supported by large RCTs (SURMOUNT-1, 2, 3, SUMMIT) with significant results.
Source
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Prabhash Chand Manoria · Cureus · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →